Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Jennifer I. Hare(Shirley Ryan AbilityLab), Simon T. Barry(AstraZeneca (Singapore))
Cited by 1,140
Related Papers
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
|Molecular Cancer Therapeutics|2011|88
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
|Journal for ImmunoTherapy of Cancer|2018|87